Targeting Tumour Heterogeneity through sequential timing of anti-hallmark combination therapies -a hypothesis for...

Area of Science:

• Oncology
• Cancer Biology
• Immunology

Background:

• Personalized medicine has advanced cancer treatment, yet challenges persist, particularly for patients with treatment-resistant cancers.
• Epithelial-mesenchymal plasticity (EMP), cancer stem cell evolution, and extracellular matrix (ECM) remodeling are critical barriers to effective cancer therapy.
• The tumor microenvironment (TME) is reprogrammed by signaling axes, including hypoxia-reactive oxygen species (ROS)-hypoxia-inducible factor-1α (HIF-1α)-transforming growth factor-β (TGF-β), promoting tumor progression and immune suppression.

Purpose of the Study:

• To systematically review the molecular mechanisms of EMP, tumor heterogeneity, and cancer hallmarks.
• To explore pharmacological strategies targeting tumor burden, epigenetic states, and immune-editing functions.
• To propose a novel Combinations, Timing, and Sequencing (CTS) protocol for integrated cancer therapy.

Main Methods:

• Systematic review of molecular mechanisms underlying EMP, tumor heterogeneity, and cancer hallmarks.
• Analysis of pharmacological strategies for targeting tumor burden and epigenetic modifications.
• Integration of vascular normalization, epigenetic modifiers, radiotherapy, chemotherapy, and immunotherapy optimization.

Main Results:

• EMP, tumor heterogeneity, and TME reprogramming are significant obstacles in cancer treatment.
• The proposed CTS protocol integrates multiple therapeutic modalities to address these challenges.
• The CTS protocol aims to revert mesenchymal phenotypes, normalize vasculature, and rescue the immune-suppressive TME.

Conclusions:

• The CTS protocol offers a novel strategy to overcome treatment resistance by targeting key cancer hallmarks.
• By reverting mesenchymal phenotypes and normalizing vasculature, the CTS protocol can reduce immunosuppressive cell recruitment.
• This approach has the potential to convert "cold" tumors into "hot" tumors responsive to immunotherapy, improving patient outcomes.